Loading company details...
Beta
Latest Form 4 (Oct 19, 2026): Ian Ying Woo (Director): Exercise/Conversion of 13,271 shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 19, 2026 | Ian Ying Woo | Exercise/Conversion | 13,271 | n/a |
| Sep 21, 2026 | Phillip Andrew Dennis, Chief Medical Officer | Exercise/Conversion | 23,695 | n/a |
| Sep 11, 2026 | Sean Wuxiong Cao, Chief Bus. Development Officer | Sale | 107,978 | $79.9K |
| Sep 8, 2026 | Sean Wuxiong Cao, Chief Bus. Development Officer | Exercise/Conversion | 235,136 | n/a |
| Sep 1, 2026 | Cong Claire Xu, EVP, Clinical Development | Exercise/Conversion | 9,382 | n/a |
| Aug 25, 2026 | Robert A. Lenz | Exercise/Conversion | 17,218 | n/a |
| Jul 10, 2026 | Mark Arnold Hagler, Chief Commercial Officer | Grant/Award | 949,050 | n/a |
| Jul 10, 2026 | Liwei Lorraine Lin, General Counsel | Grant/Award | 254,780 | n/a |
| Jul 8, 2026 | Srishti Gupta, Chief Executive Officer | Grant/Award | 3,000,000 | n/a |
| Jul 7, 2026 | Cong Claire Xu, SVP, Clinical Development | Exercise/Conversion | 12,432 | n/a |